Neumora Therapeutics, Inc.(NMRA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NMRA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Neumora Therapeutics, Inc. (NMRA), a Healthcare sector company. NMRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of NMRA by reported 13-F value include Siren, L.L.C., BlackRock, SOFTBANK GROUP, based on the most recent SEC filings. NMRA trades on the Nasdaq exchange and files with the SEC under CIK 1885522. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NMRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neumora Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-43.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+2.8% YoYOperating Income
+8.5% YoYEPS (Diluted)
+5.2% YoYTotal Assets
-39.7% YoYTotal Debt
Op. Cash Flow
-12.8% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-236.9M +2.8% | $-243.8M -3.3% | $-235.9M -80.2% | $-130.9M | — |
| Operating Income | $-241.2M +8.5% | $-263.5M -4.5% | $-252.1M -85.5% | $-135.9M | — |
| EPS (Diluted) | $-1.45 +5.2% | $-1.53 +57.9% | $-3.63 -277.3% | $-0.96 | — |
| Total Assets | $191.0M -39.7% | $317.0M -36.1% | $496.2M +16.4% | $426.2M | — |
| Total Debt | $114.5M | $0.00 | — | — | — |
| Operating Cash Flow | $-206.4M -12.8% | $-182.9M -12.0% | $-163.3M -42.1% | $-114.9M | — |
| Free Cash Flow | — | — | $-163.4M -41.6% | $-115.4M | — |
Get alerted when NMRA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Neumora Therapeutics, Inc. including:
Top Institutional Holders of NMRA
Siren, L.L.C.
$14.4M8,497,822 shBlackRock, Inc.
$13.2M7,791,869 shSOFTBANK GROUP CORP.
$10.4M6,090,301 shVANGUARD CAPITAL MANAGEMENT LLC
$7.9M4,669,585 shMIC Capital Management UK LLP
$7.6M4,460,700 shTUDOR INVESTMENT CORP ET AL
$6.5M3,835,200 shFMR LLC
$5.9M3,498,869 shWELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST
$5.6M3,309,123 shGEODE CAPITAL MANAGEMENT, LLC
$4.4M2,607,289 shICONIQ Capital, LLC
$4.4M2,559,090 sh
| Fund | Value | Shares |
|---|---|---|
| Siren, L.L.C. | $14.4M | 8,497,822 |
| BlackRock, Inc. | $13.2M | 7,791,869 |
| SOFTBANK GROUP CORP. | $10.4M | 6,090,301 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.9M | 4,669,585 |
| MIC Capital Management UK LLP | $7.6M | 4,460,700 |
| TUDOR INVESTMENT CORP ET AL | $6.5M | 3,835,200 |
| FMR LLC | $5.9M | 3,498,869 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $5.6M | 3,309,123 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.4M | 2,607,289 |
| ICONIQ Capital, LLC | $4.4M | 2,559,090 |
More Healthcare Companies
View all Healthcare →Put NMRA on your watchlist
Track score changes the day Neumora Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NMRA a good stock to buy?
13F Pro's AI-powered analysis of Neumora Therapeutics, Inc. (NMRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NMRA are available on the NMRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NMRA is classified as a small company.
Which hedge funds own NMRA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NMRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neumora Therapeutics, Inc.'s investment landscape.